search
Back to results

Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Atorvastatin Calcium Tablets, 80 mg
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy focused on measuring Bioequivalence, Atorvastatin calcium, crossover

Eligibility Criteria

18 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Subjects aged between 18 and 45 years (both inclusive).
  2. Subjects' weight within normal range according to normal values for Body Mass Index (1 8.5 to 24.9 kg/m2) with minimum of 50 kg weight.
  3. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations (Annexure IIIa) within the clinically acceptable reference range (Annexure IIIb).
  4. Subjects having normal 12-lead electrocardiogram (ECG).
  5. Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6 months prior to the dosing of Period 0 1.
  6. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine).
  7. Subjects having negative alcohol breath test.
  8. Subjects willing to adhere to the protocol requirements and to provide written informed consent.

Exclusion Criteria:

Subjects will be excluded from the study, if they meet any of the following criteria:

  1. Hypersensitivity to Atorvastatin or related class of drugs.
  2. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder.
  3. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting.
  4. History or presence of significant alcoholism or drug abuse in the past one year.
  5. History or presence of significant smoking (more than 10 cigarettes or beedi's/day).
  6. History or presence of asthma, urticaria or other significant allergic reactions.
  7. History or presence of significant gastric andlor duodenal ulceration.
  8. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  9. History or presence of cancer.
  10. Difficulty with donating blood.
  11. Difficulty in swallowing solids like tablets or capsules.
  12. Use of any prescribed or OTC medication during last two weeks prior to dosing in period 0 1.
  13. Major illness during 3 months before screening.
  14. Participation in a drug research study within past 3 months.
  15. Donation of blood in the past 3 months before screening.
  16. Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol for within 48 hours prior to dosing.
  17. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
  18. History or presence of significant easy bruising or bleeding.
  19. History or presence of significant recent trauma.

Sites / Locations

  • Veeda Clinical Research Pvt. Ltd.,

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Atorvastatin Calcium Tablets, 80 mg

Lipitor 80 mg Tablets

Arm Description

Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited

Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals

Outcomes

Primary Outcome Measures

Area under curve (AUC)

Secondary Outcome Measures

Full Information

First Posted
July 18, 2012
Last Updated
July 19, 2012
Sponsor
Dr. Reddy's Laboratories Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01645423
Brief Title
Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions
Official Title
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fed Conditions
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
August 2009 (undefined)
Primary Completion Date
September 2009 (Actual)
Study Completion Date
September 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Reddy's Laboratories Limited

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to compare and evaluate the single-dose oral bioavailability and to monitor the safety of subjects.
Detailed Description
An open label, balanced, randomized, two-treatment, two-period, two-way crossover oral bioequivalence' study of Atorvastatin Calcium 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals in healthy adult, human subjects under fed conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Bioequivalence, Atorvastatin calcium, crossover

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
77 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Atorvastatin Calcium Tablets, 80 mg
Arm Type
Experimental
Arm Description
Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Laboratories Limited
Arm Title
Lipitor 80 mg Tablets
Arm Type
Active Comparator
Arm Description
Lipitor 80 mg Tablets of Pfizer Ireland Pharmaceuticals
Intervention Type
Drug
Intervention Name(s)
Atorvastatin Calcium Tablets, 80 mg
Other Intervention Name(s)
Lipitor 80 mg Tablets
Intervention Description
Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Primary Outcome Measure Information:
Title
Area under curve (AUC)
Time Frame
Pre-dose at 0.00 hour and post-dose at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50 1.75, 2.00, 2.25,2.50, 2.75, 3.00, 3.33, 3.67,4.00,4.50, 5.00,6.00, 8.00, 10.00, 12.00, 16.00,24.00, 36.00, 48.00 and 72.00 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects aged between 18 and 45 years (both inclusive). Subjects' weight within normal range according to normal values for Body Mass Index (1 8.5 to 24.9 kg/m2) with minimum of 50 kg weight. Subjects with normal health as determined by personal medical history, clinical examination and laboratory examinations (Annexure IIIa) within the clinically acceptable reference range (Annexure IIIb). Subjects having normal 12-lead electrocardiogram (ECG). Subjects having normal chest X-Ray (P/A view) whose X-Ray was taken not more than 6 months prior to the dosing of Period 0 1. Subjects having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine, and morphine). Subjects having negative alcohol breath test. Subjects willing to adhere to the protocol requirements and to provide written informed consent. Exclusion Criteria: Subjects will be excluded from the study, if they meet any of the following criteria: Hypersensitivity to Atorvastatin or related class of drugs. History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder. Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 1 month of the study starting. History or presence of significant alcoholism or drug abuse in the past one year. History or presence of significant smoking (more than 10 cigarettes or beedi's/day). History or presence of asthma, urticaria or other significant allergic reactions. History or presence of significant gastric andlor duodenal ulceration. History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor. History or presence of cancer. Difficulty with donating blood. Difficulty in swallowing solids like tablets or capsules. Use of any prescribed or OTC medication during last two weeks prior to dosing in period 0 1. Major illness during 3 months before screening. Participation in a drug research study within past 3 months. Donation of blood in the past 3 months before screening. Consumption of grapefruit juice, xanthine-containing products, tobacco containing products or alcohol for within 48 hours prior to dosing. Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C. History or presence of significant easy bruising or bleeding. History or presence of significant recent trauma.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Dharmesh Domadia, MD
Organizational Affiliation
Veeda Clinical Research Pvt. Ltd.,
Official's Role
Principal Investigator
Facility Information:
Facility Name
Veeda Clinical Research Pvt. Ltd.,
City
Ahmedabad
State/Province
Gujrat
ZIP/Postal Code
3 80015,
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions

We'll reach out to this number within 24 hrs